The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach

被引：0
|
作者：
Christoph U. Correll
Craig Chepke
Paul Gionfriddo
Joe Parks
Phyllis Foxworth
Anirban Basu
Teri S. Brister
Dawn Brown
Christopher Clarke
Youssef Hassoun
机构：
[1] The Zucker Hillside Hospital,The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, Departments of Pharmacy, Health Services, and Economics
[2] Department of Psychiatry Research,Enterprise Digital Health
[3] Northwell Health,undefined
[4] Donald and Barbara Zucker School of Medicine at Hofstra/Northwell,undefined
[5] Department of Psychiatry and Molecular Medicine,undefined
[6] Charité Universitätsmedizin Berlin,undefined
[7] Department of Child and Adolescent Psychiatry,undefined
[8] Excel Psychiatric Associates,undefined
[9] Mental Health America,undefined
[10] National Council for Behavioral Health,undefined
[11] Depression and Bipolar Support Alliance,undefined
[12] University of Washington,undefined
[13] National Alliance on Mental Illness,undefined
[14] University of Southern California,undefined
来源：
BMC Psychiatry | / 22卷
关键词：
Bipolar I disorder; Collaborative-care; COVID-19; Long-acting injectable antipsychotics; Schizophrenia;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 9 条
  • [1] The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach
    Correll, Christoph U.
    Chepke, Craig
    Gionfriddo, Paul
    Parks, Joe
    Foxworth, Phyllis
    Basu, Anirban
    Brister, Teri S.
    Brown, Dawn
    Clarke, Christopher
    Hassoun, Youssef
    BMC PSYCHIATRY, 2022, 22 (01)
  • [2] Early use of long-acting injectable antipsychotics in bipolar disorder type I: An expert consensus
    Vieta, Eduard
    Tohen, Mauricio
    Mcintosh, Diane
    Kessing, Lars Vedel
    Sajatovic, Martha
    Mcintyre, Roger S.
    BIPOLAR DISORDERS, 2025, 27 (01) : 7 - 16
  • [3] Long-acting injectable antipsychotics as maintenance therapy for schizophrenia during the COVID-19 pandemic: A micro-narrative review
    Oguchi, Yoshiyo
    Miyake, Nobumi
    Ando, Kumiko
    NEUROPSYCHOPHARMACOLOGY REPORTS, 2024, 44 (01) : 34 - 41
  • [4] Changes in Clinical Management of Patients with Schizophrenia Treated with Long-Acting Injectable Antipsychotics (LAIs), Including Telepsychiatry Use, During the COVID-19 Pandemic
    Haider, Batool
    O'Sullivan, Amy K.
    Bessonova, Leona
    Keane, Elizabeth
    Achtyes, Eric
    Harvey, Philip
    Kane, John M.
    Saklad, Stephen R.
    Trotter, Jeffrey P.
    Claxton, Amy
    Polak, Tiffany
    McGrory, James
    Noori, Wahidullah
    Kessler, Asia Sikora
    Yarlas, Aaron
    Velligan, Dawn
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2023, 19 : 623 - 634
  • [5] Impact of COVID-19 Pandemic on Prescribing of Long-Acting Injectable Antipsychotics for Schizophrenia: Results from a United States Prescriber Survey
    Zhdanava, Maryia
    Starr, H. Lynn
    Totev, Todor, I
    Lefebvre, Patrick
    Shah, Aditi
    Sheng, Kristy
    Pilon, Dominic
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2022, 18 : 2003 - 2019
  • [6] Long-acting Injectable Antipsychotics during the COVID-19 pandemic in schizophrenia: An observational study in a real-world clinical setting
    Barlati, Stefano
    Nibbio, Gabriele
    Bianchi, Francesco
    Gigli, Elena Butti Lemmi
    Calzavara-Pinton, Irene
    Cerati, Caterina
    Fiori, Jacopo
    Lisoni, Jacopo
    Deste, Giacomo
    Vita, Antonio
    PSYCHIATRY RESEARCH, 2022, 317
  • [7] Earlier Use of Long-Acting Injectable Paliperidone Palmitate Versus Oral Antipsychotics in Patients With Schizophrenia: An Integrated Patient-Level Post Hoc Analysis
    Lopena, Oliver J.
    Alphs, Larry D.
    Sajatovic, Martha
    Turkoz, Ibrahim
    Sun, Liping
    Johnston, Karen L.
    Sliwa, Jennifer K.
    Najarian, Dean M.
    Starr, H. Lynn
    JOURNAL OF CLINICAL PSYCHIATRY, 2023, 84 (06)
  • [8] Population Pharmacokinetics and Dosing Simulations for Aripiprazole 2-Month Ready-to-Use Long-Acting Injectable in Adult Patients With Schizophrenia or Bipolar I Disorder
    Wang, Yanlin
    Harlin, Matthew
    Larsen, Frank
    Wang, Xiaofeng
    Park, Wansu
    Rich, Benjamin
    Gobburu, Jogarao V.
    Raoufinia, Arash
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (06): : 631 - 643
  • [9] Utilization of long-acting injectable monthly depot buprenorphine for opioid use disorder (OUD) in Kentucky, before and after COVID-19 related buprenorphine access policy changes
    Hammerslag, Lindsey R.
    Talbert, Jeffery
    Slavova, Svetla
    Lei, Feitong
    Freeman, Patricia R.
    Marks, Katherine R.
    Fanucchi, Laura C.
    Walsh, Sharon L.
    Lofwall, Michelle R.
    JOURNAL OF SUBSTANCE USE & ADDICTION TREATMENT, 2024, 164
1